$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

$snoa Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000168316823005508 Filed on August 10, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$2.731M	$3.427M	$3.983M
YoY Change	-18.01%	-13.96%	8.12%
Cost Of Revenue	$1.741M	$2.223M	$2.537M
YoY Change	-12.73%	-12.38%	13.72%
Gross Profit	$990.0K	$1.204M	$1.446M
YoY Change	-25.9%	-16.74%	-0.48%
Gross Profit Margin	36.25%	35.13%	36.3%
Selling, General & Admin	$1.662M	$2.119M	$2.295M
YoY Change	-19.59%	-7.67%	0.97%
% of Gross Profit	167.88%	176.0%	158.71%
Research & Development	$536.0K	$325.0K	$6.000K
YoY Change		5316.67%	-92.86%
% of Gross Profit	54.14%	26.99%	0.41%
Depreciation & Amortization	$40.00K	$45.00K	$31.00K
YoY Change	42.86%	45.16%	-35.42%
% of Gross Profit	4.04%	3.74%	2.14%
Operating Expenses	$2.198M	$2.444M	$2.301M
YoY Change	6.34%	6.21%	-2.38%
Operating Profit	-$1.208M	-$1.240M	-$855.0K
YoY Change	65.25%	45.03%	-5.42%
Interest Expense			$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	-$90.00K	-$211.0K	-$67.00K
YoY Change	-52.38%	214.93%	-65.28%
Pretax Income	-$1.298M	-$1.451M	-$922.0K
YoY Change	41.55%	57.38%	-16.03%
Income Tax	$186.0K	-$33.00K	-$35.00K
% Of Pretax Income
Net Earnings	-$1.484M	-$1.418M	-$887.0K
YoY Change	45.92%	59.86%	-19.22%
Net Earnings / Revenue	-54.34%	-41.38%	-22.27%
Basic Earnings Per Share	-$0.29	-$0.29	-$0.29
Diluted Earnings Per Share	-$0.29	-$0.29	-$0.29
COMMON SHARES
Basic Shares Outstanding	5.143M shares	4.942M shares	3.101M shares
Diluted Shares Outstanding	5.164K shares	4.936K shares	3.101M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.140M	$3.544M	$5.586M
YoY Change	-36.14%	-36.56%	98.72%
Cash & Equivalents	$2.137M	$3.544M	$5.586M
Short-Term Investments
Other Short-Term Assets	$4.650M	$4.874M	$4.009M
YoY Change	31.73%	21.58%	7.54%
Inventory	$2.513M	$2.730M	$2.788M
Prepaid Expenses
Receivables	$2.223M	$2.439M	$2.434M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$11.52M	$13.59M	$14.82M
YoY Change	-7.08%	-8.3%	21.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$433.0K	$485.0K	$309.0K
YoY Change	41.97%	56.96%	-71.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$75.00K	$77.00K	$112.0K
YoY Change	-68.49%	-31.25%	-87.11%
Total Long-Term Assets	$2.119M	$2.306M	$2.341M
YoY Change	-17.52%	-1.5%	19.2%
TOTAL ASSETS
Total Short-Term Assets	$11.52M	$13.59M	$14.82M
Total Long-Term Assets	$2.119M	$2.306M	$2.341M
Total Assets	$13.64M	$15.89M	$17.16M
YoY Change	-8.87%	-7.37%	21.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$987.0K	$1.090M	$2.057M
YoY Change	-8.1%	-47.01%	12.34%
Accrued Expenses	$1.920M	$2.488M	$2.185M
YoY Change	-7.29%	13.87%	50.07%
Deferred Revenue
YoY Change
Short-Term Debt	$170.0K	$301.0K	$459.0K
YoY Change	-25.76%	-34.42%	15.62%
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.239M	$4.041M	$4.854M
YoY Change	-8.17%	-16.75%	-7.24%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$15.00K
YoY Change	-100.0%	-100.0%
Other Long-Term Liabilities	$4.720M	$4.610M	$4.330M
YoY Change	7.3%	6.47%	1.48%
Total Long-Term Liabilities	$4.720M	$4.610M	$15.00K
YoY Change	31366.67%	30633.33%	-99.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.239M	$4.041M	$4.854M
Total Long-Term Liabilities	$4.720M	$4.610M	$15.00K
Total Liabilities	$7.960M	$8.651M	$9.199M
YoY Change	0.24%	-5.96%	-3.17%
SHAREHOLDERS EQUITY
Retained Earnings	-$192.4M	-$190.9M	-$185.3M
YoY Change	3.3%	3.07%
Common Stock	$201.2M	$201.1M	$197.6M
YoY Change	1.78%	1.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.675M	$7.242M	$7.959M
YoY Change
Total Liabilities & Shareholders Equity	$13.64M	$15.89M	$17.16M
YoY Change	-8.87%	-7.37%	21.51%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$1.484M	-$1.418M	-$887.0K
YoY Change	45.92%	59.86%	-19.22%
Depreciation, Depletion And Amortization	$40.00K	$45.00K	$31.00K
YoY Change	42.86%	45.16%	-35.42%
Cash From Operating Activities	-$1.230M	-$215.0K	-$1.533M
YoY Change	-32.79%	-85.98%	25.35%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$17.00K	$23.00K
YoY Change	-100.0%	-26.09%	-53.06%
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$17.00K	-$23.00K
YoY Change	-100.0%	-26.09%	-53.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	-$135.0K	-$387.0K
YoY Change	-32.58%	-65.12%	85.17%
NET CHANGE
Cash From Operating Activities	-1.230M	-$215.0K	-$1.533M
Cash From Investing Activities	0.000	-$17.00K	-$23.00K
Cash From Financing Activities	-120.0K	-$135.0K	-$387.0K
Net Change In Cash	-1.350M	-$276.0K	-$1.810M
YoY Change	-38.5%	-84.75%	28.46%
FREE CASH FLOW
Cash From Operating Activities	-$1.230M	-$215.0K	-$1.533M
Capital Expenditures	$0.00	$17.00K	$23.00K
Free Cash Flow	-$1.230M	-$232.0K	-$1.556M
YoY Change	-31.86%	-85.09%	22.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001367083
CY2023Q2	dei	Amendment Flag AmendmentFlag	false
CY2023Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2023Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	dei	Document Type DocumentType	10-Q
CY2023Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q2	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
CY2023Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q2	dei	Entity File Number EntityFileNumber	001-33216
CY2023Q2	dei	Entity Registrant Name EntityRegistrantName	SONOMA PHARMACEUTICALS, INC.
CY2023Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	68-0423298
CY2023Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	5445 Conestoga Court
CY2023Q2	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2023Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Boulder
CY2023Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2023Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80301
CY2023Q2	dei	City Area Code CityAreaCode	(800)
CY2023Q2	dei	Local Phone Number LocalPhoneNumber	759-9305
CY2023Q2	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2023Q2	dei	Trading Symbol TradingSymbol	SNOA
CY2023Q2	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q2	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5142769	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3544000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3820000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2439000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2572000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2730000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4621000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4308000	usd
CY2023Q2	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	253000	usd
CY2023Q1	SNOA	Deferred Consideration Net Current DeferredConsiderationNetCurrent	240000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	13587000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	13798000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	485000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	488000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	354000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2023Q2	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	908000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	949000	usd
CY2023Q2	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	482000	usd
CY2023Q1	SNOA	Deferred Consideration Net Noncurrent DeferredConsiderationNetNoncurrent	505000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	77000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	73000	usd
CY2023Q2	us-gaap	Assets Assets	15893000	usd
CY2023Q1	us-gaap	Assets Assets	16231000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1090000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	841000	usd
CY2023Q2	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2255000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	2029000	usd
CY2023Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	100000	usd
CY2023Q2	SNOA	Contract With Customer Liability Current Invekra ContractWithCustomerLiabilityCurrentInvekra	62000	usd
CY2023Q1	SNOA	Contract With Customer Liability Current Invekra ContractWithCustomerLiabilityCurrentInvekra	60000	usd
CY2023Q2	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	301000	usd
CY2023Q1	us-gaap	Other Long Term Debt Current OtherLongTermDebtCurrent	431000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	4041000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3717000	usd
CY2023Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	132000	usd
CY2023Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	140000	usd
CY2023Q2	SNOA	Withholding Tax Payable WithholdingTaxPayable	4357000	usd
CY2023Q1	SNOA	Withholding Tax Payable WithholdingTaxPayable	4235000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	8651000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	8254000	usd
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5141596	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5141596	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4933550	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4933550	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	201076000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	200904000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190932000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2907000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3418000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7242000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	15893000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16231000	usd
CY2023Q2	us-gaap	Revenues Revenues	3427000	usd
CY2022Q2	us-gaap	Revenues Revenues	3983000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2223000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2337000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	1204000	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	1646000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	325000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	206000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2119000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2295000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	2444000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	2501000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1240000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-855000	usd
CY2023Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-211000	usd
CY2022Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-67000	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-94000	usd
CY2023Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1451000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-922000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-33000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-35000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-887000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4936	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4936	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3101	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3101	shares
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-887000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	511000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-65000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-907000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-952000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-887000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	45000	usd
CY2022Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	31000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	177000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	214000	usd
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	90000	usd
CY2022Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-40000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-191000	usd
CY2022Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	73000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-230000	usd
CY2022Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	175000	usd
CY2023Q2	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	49000	usd
CY2022Q2	SNOA	Increase Decrease In Deferred Consideration Net Of Discount IncreaseDecreaseInDeferredConsiderationNetOfDiscount	41000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	84000	usd
CY2022Q2	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	76000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-79000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-31000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	214000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	423000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	180000	usd
CY2022Q2	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	114000	usd
CY2023Q2	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	122000	usd
CY2022Q2	SNOA	Increase Decrease In Withholding Tax Payable IncreaseDecreaseInWithholdingTaxPayable	95000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-79000	usd
CY2022Q2	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1137000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-215000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1533000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	usd
CY2022Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	23000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23000	usd
CY2023Q2	SNOA	Payment On Atm Agreement Offering PaymentOnAtmAgreementOffering	5000	usd
CY2022Q2	SNOA	Payment On Atm Agreement Offering PaymentOnAtmAgreementOffering	-0	usd
CY2023Q2	SNOA	Payments On Ppp Loan PaymentsOnPppLoan	-0	usd
CY2022Q2	SNOA	Payments On Ppp Loan PaymentsOnPppLoan	120000	usd
CY2023Q2	SNOA	Payment Of Longterm Deposits PaymentOfLongtermDeposits	-0	usd
CY2022Q2	SNOA	Payment Of Longterm Deposits PaymentOfLongtermDeposits	37000	usd
CY2023Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	130000	usd
CY2022Q2	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	230000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-135000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-387000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	91000	usd
CY2022Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	133000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-276000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1810000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3820000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7396000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3544000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5586000	usd
CY2023Q2	us-gaap	Interest Paid Net InterestPaidNet	5000	usd
CY2022Q2	us-gaap	Interest Paid Net InterestPaidNet	4000	usd
CY2023Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q2	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	55000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7977000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-5000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	177000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	511000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-1418000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	7242000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	8697000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	214000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-65000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-887000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	7959000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-887000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190932000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-189514000	usd
CY2023Q2	SNOA	Working Capital WorkingCapital	9546000	usd
CY2023Q1	SNOA	Working Capital WorkingCapital	10081000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-215000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1395000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1764000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1335000	usd
CY2022Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1533000	usd
CY2023Q2	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_840_eus-gaap--UseOfEstimates_zYraZY39Bs99" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_869_znAFmMPUNyil">Use of Estimates</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.5pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates and assumptions include reserves and write-downs related to receivables and inventories, the valuation allowance relating to the Company’s deferred tax assets, valuation of equity and the estimated amortization periods of upfront product licensing fees received from customers. Periodically, the Company evaluates and adjusts estimates accordingly.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_847_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zz7JV1YfatY9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i><span id="xdx_86F_zJQZVkN7wfW">Reclassification</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended June 30, 2023, the Company aligned its accounting policy to conform the presentation of certain costs it views as research and development efforts. These costs are now included in research and development, whereas they were previously included in cost of revenues. The three months ended June 30, 2022 has been reclassified to conform to the current period presentation. The reclassification increased research and development by $<span id="xdx_907_ecustom--IncreaseResearchAndDevelopmentInProcess_pn3p0_c20230401__20230630_zXbc4nfQBJn9" title="Increase research and development in process">200,000</span> and decreased cost of revenues by the same amount. The reclassification had no impact on total operating costs, earnings from operations, net earnings, earnings per share or total equity.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q2	SNOA	Increase Research And Development In Process IncreaseResearchAndDevelopmentInProcess	200000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-1418000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-887000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4936	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4936	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3101	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3101	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1094000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	2730000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	2858000	usd
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	727000	shares
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	602000	shares
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q2	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	17000	usd
CY2023Q1	SNOA	Allowance For Sales Discounts Rebates Distributor Fees And Returns AllowanceForSalesDiscountsRebatesDistributorFeesAndReturns	16000	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	247000	usd
CY2023Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	236000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	354000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	418000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	233000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	256000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	121000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	103000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	79000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P17Y4M24D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0600	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	239000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	141000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	16000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	396000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	354000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3427000	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	24000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	177000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	214000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3983000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3427000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3983000	usd

Files In Submission

Name	View Source	Status
0001683168-23-005508-index-headers.html	Edgar Link	pending
0001683168-23-005508-index.html	Edgar Link	pending
0001683168-23-005508.txt	Edgar Link	pending
0001683168-23-005508-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
snoa-20230630.xsd	Edgar Link	pending
sonoma_ex3101.htm	Edgar Link	pending
sonoma_ex3102.htm	Edgar Link	pending
sonoma_ex3201.htm	Edgar Link	pending
sonoma_i10q-063023.htm	Edgar Link	pending
snoa-20230630_def.xml	Edgar Link	unprocessable
snoa-20230630_lab.xml	Edgar Link	unprocessable
sonoma_i10q-063023_htm.xml	Edgar Link	completed
snoa-20230630_pre.xml	Edgar Link	unprocessable
snoa-20230630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa

2023 Q3 Form 10-Q Financial Statement

#000168316823005508 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA Sonoma Pharmaceuticals, Inc. Stock $snoa

2023 Q3 Form 10-Q Financial Statement

#000168316823005508 Filed on August 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SNOA
Sonoma Pharmaceuticals, Inc. Stock $snoa